NuVasive, Inc. (NASDAQ:NUVA) – Research analysts at Gabelli upped their FY2019 earnings per share estimates for shares of NuVasive in a research note issued to investors on Monday. Gabelli analyst J. Tsai now forecasts that the medical device company will post earnings of $2.85 per share for the year, up from their prior estimate of $2.80. Gabelli currently has a “Buy” rating on the stock. Gabelli also issued estimates for NuVasive’s FY2021 earnings at $4.00 EPS.

Several other analysts have also recently weighed in on the stock. Barclays PLC reissued a “buy” rating and issued a $80.00 price target on shares of NuVasive in a research note on Wednesday. BidaskClub cut shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Monday. Zacks Investment Research cut shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Monday. Cowen and Company reissued an “outperform” rating and issued a $83.00 price target (down previously from $90.00) on shares of NuVasive in a research note on Sunday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $79.00 price target on shares of NuVasive in a research note on Sunday. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. NuVasive presently has a consensus rating of “Buy” and a consensus price target of $81.18.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/03/fy2019-eps-estimates-for-nuvasive-inc-nuva-boosted-by-analyst.html.

Shares of NuVasive (NASDAQ NUVA) traded down 0.69% during mid-day trading on Tuesday, reaching $63.56. 998,674 shares of the company’s stock traded hands. The stock has a market capitalization of $3.23 billion, a PE ratio of 100.09 and a beta of 1.06. The company’s 50-day moving average price is $76.85 and its 200-day moving average price is $74.43. NuVasive has a 12-month low of $56.70 and a 12-month high of $81.68.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million during the quarter, compared to analyst estimates of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.40 earnings per share.

Large investors have recently made changes to their positions in the company. Teachers Advisors LLC increased its position in shares of NuVasive by 205.8% in the first quarter. Teachers Advisors LLC now owns 249,546 shares of the medical device company’s stock worth $18,636,000 after buying an additional 167,950 shares during the period. Keybank National Association OH increased its position in NuVasive by 0.7% in the first quarter. Keybank National Association OH now owns 12,667 shares of the medical device company’s stock valued at $946,000 after buying an additional 86 shares during the period. Columbus Circle Investors increased its position in NuVasive by 7.9% in the first quarter. Columbus Circle Investors now owns 745,483 shares of the medical device company’s stock valued at $55,673,000 after buying an additional 54,291 shares during the period. Stephens Investment Management Group LLC increased its position in NuVasive by 7.5% in the first quarter. Stephens Investment Management Group LLC now owns 685,623 shares of the medical device company’s stock valued at $51,202,000 after buying an additional 47,707 shares during the period. Finally, Pacer Advisors Inc. increased its position in NuVasive by 22.0% in the first quarter. Pacer Advisors Inc. now owns 5,244 shares of the medical device company’s stock valued at $392,000 after buying an additional 945 shares during the period.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.